Jump Financial LLC Takes Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Jump Financial LLC purchased a new position in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 55,720 shares of the biotechnology company's stock, valued at approximately $1,062,000. Jump Financial LLC owned approximately 0.10% of Alpine Immune Sciences at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Walleye Capital LLC lifted its position in shares of Alpine Immune Sciences by 13.1% in the third quarter. Walleye Capital LLC now owns 186,273 shares of the biotechnology company's stock worth $2,133,000 after buying an additional 21,600 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Alpine Immune Sciences by 429.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,723 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 5,454 shares during the period. Vanguard Group Inc. lifted its stake in shares of Alpine Immune Sciences by 5.1% in the third quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company's stock worth $16,887,000 after buying an additional 70,912 shares during the last quarter. Nan Fung Group Holdings Ltd acquired a new position in Alpine Immune Sciences in the 3rd quarter valued at $2,087,000. Finally, Schonfeld Strategic Advisors LLC raised its holdings in Alpine Immune Sciences by 604.9% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 90,937 shares of the biotechnology company's stock worth $1,041,000 after acquiring an additional 78,037 shares during the period. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Price Performance

Shares of Alpine Immune Sciences stock traded up $0.01 during midday trading on Friday, hitting $64.97. 4,288,333 shares of the company were exchanged, compared to its average volume of 1,875,865. The firm has a 50 day simple moving average of $52.56 and a 200-day simple moving average of $32.51. The firm has a market cap of $4.46 billion, a P/E ratio of -101.52 and a beta of 0.97. Alpine Immune Sciences, Inc. has a 52 week low of $8.33 and a 52 week high of $65.00.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative return on equity of 14.86% and a negative net margin of 65.17%. The company had revenue of $30.85 million during the quarter, compared to analysts' expectations of $6.90 million. Equities research analysts expect that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Morgan Stanley reaffirmed an "equal weight" rating and issued a $65.00 target price (up previously from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. SVB Leerink downgraded shares of Alpine Immune Sciences from an "outperform" rating to a "market perform" rating and boosted their price objective for the stock from $42.00 to $65.00 in a report on Friday, April 12th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $65.00 target price (up previously from $41.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. TD Cowen restated a "hold" rating on shares of Alpine Immune Sciences in a research note on Tuesday, April 16th. Finally, Guggenheim began coverage on Alpine Immune Sciences in a research report on Tuesday, April 9th. They issued a "buy" rating and a $55.00 price objective for the company. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Alpine Immune Sciences has an average rating of "Hold" and a consensus price target of $52.33.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.